Amplifon continues its fall, analysts cautious on GN Hearing | EUROtoday

Listen to the audio model of the article

(Il Sole 24 Ore Radiocor) Sales on Amplifon don’t cease whereas the market evaluates the results of the acquisition of GN Hearing. The inventory, which yesterday had left 14% of its worth on the bottom, marks the worst efficiency of the Ftse Mib. Amplifon yesterday introduced the acquisition of GN Hearing for two.3 billion euros, thus marking the transition from a pure listening to help retailer to a vertically built-in chief. An operation that analysts outline as “complex” particularly on the monetary entrance and which comes at a difficult time, however whose industrial logic additionally they underline, even when the goal cuts spotlight the penalization of valuations within the brief time period additionally because of the dilutive impact of the capital improve. The change in technique includes an operation which, from a monetary viewpoint, supplies for a consideration that shall be paid within the quantity of roughly 1.69 billion in money and 56 million in new Amplifon shares. The money part shall be fully financed at closing via a bridge mortgage, which Amplifon expects to refinance over time with a mix of debt and fairness, together with a potential capital improve of as much as roughly 0.75 billion euros. From an industrial viewpoint, Intermonte analysts (outperform with a goal of 16 euros) see «important synergies primarily on the quantity entrance and for a extra diversified profile, attributable to geographical and industrial complementarity». Among the elements of complexity, from a monetary viewpoint, analysts cite the anticipated capital improve. Intermonte estimates a rise in earnings per share to 2027. Analysts stay optimistic on the inventory, however with a extra cautious evaluation and minimize the goal worth to 16 from 19 euros, attributable to execution dangers, the rise in debt and monetary uncertainty. For Akros, the valuation of the acquisition “is not cheap” and “it implies a significant change in the business model for the group, which has always denied the possibility of upstream integration”. However, that is the group’s «first step to handle structural adjustments within the sector; we due to this fact imagine that it’s a mandatory step for the transformation which ought to permit the corporate higher management over prices and know-how”. Here too, target price cut to 12.50 from 14 euros, neutral confirmed. Also Mediobanca highlights “the clear change in technique” which “offers a path to reaccelerate growth in a slowing hearing aid market.” Analysts see “important and low-risk synergy potential”, however “the creation of worth within the brief time period is restricted by the anticipated dilution of income, due each to the issuing of latest shares to partially finance the operation and to a potential capital improve mandatory for the money part”. Neutral rating with target price of 11.5 euros. Equita’s analysis highlights the aspects of uncertainty, expressing doubts about the operation both for the choice to move towards a vertically integrated model «compared to what has been pursued in recent decades (in our opinion preferable for the greater operational flexibility), in timing of the operation (carried out at a time of strong derating of the stock, thus increasing the dilutive impact) and in the risks of executing synergies”. The analysts due to this fact minimize their score to carry with a goal worth of 11 euros from 20.